Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this observational study, most patients with multiple sclerosis on teriflunomide who experienced hair thinning reported it as mild or moderate and largely recovered while continuing treatment.

This study examined the FDA Adverse Events Reporting System and found new dermatologic adverse events associated with EGFR-TKIs in non-small cell lung cancer patients, such as specific skin, nail, and hair issues, that aren't currently listed on drug labels.

This study observed that renal transplant recipients had a higher incidence of infectious skin diseases, particularly human papilloma virus infections, highlighting the importance of regular dermatological screening.

In this study, both physician and patient reports revealed that more severe alopecia areata was associated with higher emotional symptoms and greater activity limitations among patients.

This study among patients with severe alopecia areata in South Korea found that 93.4% received pharmacological treatment, with 71.0% achieving hair regrowth and 59.2% experiencing major regrowth, but highlighted a critical unmet need for more effective treatment strategies.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This review discusses the guidelines for using and monitoring mood stabilizers in bipolar disorders, highlighting that only a minority of patients receive guideline-adherent monitoring.

This study identified three clusters of autoantibodies in children with systemic lupus erythematosus, each associated with specific clinical manifestations at diagnosis.

This paper reports a rare case where AL amyloidosis presented as isolated scalp alopecia, underscoring the importance of considering systemic amyloidosis in the differential diagnosis of alopecia.

This study found that cutaneous manifestations in patients undergoing hemodialysis are common and often worsen with longer treatment duration.

This review found that teledermatology was significantly used during the COVID-19 pandemic, particularly for managing common ambulatory dermatoses like acne and eczema.

Acquired perforating dermatosis often affects skin in people with kidney issues and diabetes.

Minoxidil lowers blood pressure in kids with kidney issues, but use carefully due to side effects.

Regenerative repair is essential to prevent long-term kidney function issues after obstruction.

This study found that xerosis and pruritus are prevalent in patients with chronic renal failure undergoing hemodialysis, highlighting the importance of early recognition of skin issues to alleviate discomfort and reduce complications.

This review discusses the transformative potential and challenges of using AI in cosmetic dermatology, highlighting how AI is enhancing diagnostics, treatment personalization, and patient satisfaction while addressing issues such as data quality and ethical concerns in order to ensure responsible and ethical implementation.

This study observed that nearly all kidney transplant patients experienced complications from immunosuppressive therapy, with excessive hair growth and increased blood sugar being the most common issues.

In this retrospective study, the researchers found that infectious dermatologic conditions were most common among renal transplant recipients, with viral warts being the prevalent infectious condition, while increasing age and sex were associated with varying odds of developing different dermatologic issues.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study found that dermatological issues, such as xerosis and pigmentation, are common in chronic kidney disease patients and increase with the severity and duration of the disease, indicating that dialysis often exacerbates these conditions.

Chronic kidney disease can cause hair loss, which may be related to zinc deficiency or certain medications, and sometimes hair grows back when the underlying issue is treated.

This article provides a case study on determining Regal Hair Salons Inc.'s federal income tax liability and financial reporting consistency with GAAP concerning gift card sales, with no specific new results reported.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This study conducted in the Kingdom of Saudi Arabia reported that severe alopecia areata presents significant treatment challenges due to limited therapies, leading to substantial impacts on patients' quality of life, mental health, and economic burdens.

This study reported that 83.1% of patients with end-stage renal disease on hemodialysis experienced skin conditions, with xerosis affecting 63.6%, pruritis 36.4%, and notable occurrences of nail and oral anomalies, indicating a need for targeted dermatological management to improve patients' quality of life.

This study reported that severe hypothyroidism in two pediatric patients was associated with transient liver and kidney dysfunction, which resolved after beginning levothyroxine treatment.

This study explores the controversial condition known as post‐finasteride syndrome, observed in some men who experience lasting sexual, neurological, and psychological side effects after stopping finasteride, emphasizing its rarity and the lack of proven treatments.

In this study, pruritus was the most frequent skin disorder observed in hemodialyzed patients, particularly among those undergoing long-term dialysis.

This review discusses dermatologic changes in chronic renal failure patients undergoing hemodialysis and reports no new clinical results.

This article discusses the challenges ESRD patients face with Medicare Part D, including high out-of-pocket costs and coverage gaps, but reports no new research data.